References

Barry ST, Ludbrook SB, Murrison E, Horgan CM. Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res. 2000; 258:(2)342-51 https://doi.org/10.1006/excr.2000.4941

Bloomgren G, Richman S, Hotermans C Risk of Natalizumab–associated progressive multifocal leukoencephlopathy. N Engl J Med. 2012; 366:1870-1880 https://doi.org/10.1056/NEJMoa1107829

Brandstadter R, Katz Sand I. The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat. 2017; 13:1691-1702 https://doi.org/10.2147/NDT.S114636

Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol. 2014; 21:(2)299-304 https://doi.org/10.1111/ene.12304

Bozic C, Richman S, Plavina T Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011; 70:(5)742-50 https://doi.org/10.1002/ana.22606

Calabresi PA, Giovannoni G, Confavreux C The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007; 69:1391-1403

Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 2019; 19:(2)106-114 https://doi.org/10.1136/practneurol-2018-002060

electronic Medicines Compendium. Physician* Information and Management Guidelines for Multiple Sclerosis Patients on TYSABRI Therapy. 2017. https://www.medicines.org.uk/emc/rmm/1199/Document (accessed 25 July 2019)

European Medicines Agency. Tysabri update. 2014. https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri (accessed 16 July 2019)

Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016; 16:(1) https://doi.org/10.1186/s12883-016-0674-4

Fox RJ, Cree BA, De Seze J MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014; 82:(17)1491-8

Grossman I, Knappertz V, Laifenfeld D Pharmacogenomics strategies to optimize treatments for Multiple Sclerosis: Insights from clinical research. Prog Neurobiol. 2017; 152:114-130 https://doi.org/10.1016/j.pneurobio.2016.02.001

Gueguen A, Roux P, Deschamps R Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014; 85:(9)1038-40 https://doi.org/ 10.1136/jnnp-2014-307591

Haghikia A, Langer-Gould A, Rellensmann G Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014; 71:(7)891-5 https://doi.org/10.1001/jamaneurol.2014.209

Havrdova E, Galetta S, Hutchinson M Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009; 8:(3)254-60 https://doi.org/10.1016/S1474-4422(09)70021-3

Kappos L, Bates D, Edan G Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011; 10:(8)745-58 https://doi.org/10.1016/S1474-4422(11)70149-1

Kappos L, Butzkueven H, Spelman T Real-world data from over 10 years in the TYSABRI Observational Program: long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients. ECTRIMS Online Library. 2018; 228751

Khatri BO, Man S, Giovannoni G. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009; 72:(5)402-9 https://doi.org/10.1212/01.wnl.0000341766.59028.9d

Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol. 2006; 577:19-45

McGuigan C, Craner M, Guadagno J Stratification and monitoring of natalizumab associated progressive multifocal leukoencephalopathy recommendations from expert group. J Neurol Neurosurg Psychiatry. 2016; 87:(2)117-25 https://doi.org/10.1136/jnnp-2015-311100

MS Society. Siponimod licensed in US for active secondary progressive MS. 2019a. https://www.mssociety.org.uk/what-we-do/news/siponimod-licensed-in-us-for-active-secondary-progressive-ms (accessed 25 July 2019)

MS Trust. MS: the facts. 2018. https://www.mstrust.org.uk/about-ms/what-ms/ms-facts (accessed 25 July 2019)

Polman CH, O'Connor PW, Havrdova E. A randomised placebo controlled trial on Natalizumab for relapsing remitting multiple sclerosis. N Engl J Med. 2006; 354:(9)899-910

NHS England. Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies. 2018. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2019/03/Treatment-Algorithm-for-Multiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf (accessed 16 July 2019)

Ryerson LZ, Foley J, Chang I 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program. Journal of Neurology, Neurosurgery and Psychiatry. 2018; 89

Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011; 77:(11)1061-7 https://doi.org/10.1212/WNL.0b013e31822e55e7

Tyler KL, Vollmer TL. To PLEX or not to PLEX in natalizumab-associated PML. Neurology. 2017; 88:(12)1108-1109 https://doi.org/10.1212/WNL.0000000000003747

Wattjes MP, Rovira À, Miller D Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015; 11:(10)597-606 https://doi.org/10.1038/nrneurol.2015.157

Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009; 86:(2)144-56 https://doi.org/10.1002/bdrb.20193

Wijburg MT, Witte BI, Vennegoor A. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry. 2016; 87:(10)1138-45 https://doi.org/10.1136/jnnp-2016-313772

Natalizumab for the treatment of highly active MS: risks and benefits

02 August 2019
Volume 1 · Issue 8

Abstract

This article discusses the history of natalizumab (Tysabri), the first monoclonal antibody used to treat multiple sclerosis. It reviews how the drug's difficult beginnings and controversial past has changed the treatment is monitored treatment. The article looks at the role of clinicians in maintaining patient safety, the benefits and risk profile of this treatment, and ways of optimising practice to provide gold standard nationalised natalizumab services throughout the UK.

Multiple sclerosis (MS) is the most common neurological disease in young adults, affecting about 100 000 people in the UK (MS Trust, 2018). MS is an autoimmune disease of the central nervous system (CNS), which causes demylenation. Its symptoms result from inflammatory injury and neurodegeneration. In MS, autoreactive lymphocytes cross the blood brain barrier (BBB) and enter the CNS, causing inflammation, neuronal demyelination, axonal damage, and neurological degeneration and dysfunction (Bradstander and Katz Sand, 2017).

MS is classified into three main types: relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS). RRMS affects 85% of the MS population (MS Trust, 2018). It is categorised by episodes of new or worsening symptoms that last for more than 48 hours (relapse) followed by periods of recovery and remission (remission). This type of MS is more prevalent in 20–30-year-old women. There are a number of disease modifying therapies (DMTs) that aim to reduce the impact of relapses and the accumulation of disability. Each of these treatments has different mode of action, efficacy, route of administration and licencing criteria. The medication chosen for someone with MS will be a decision for the patient and their neurologist to make together by looking at the patient's disease activity, lifestyle and life choices (ie starting a family) (NHS England, 2018).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month